Xiaokai Huang1, Jie Zhao1, Jinhong Zhu2, Shanshan Chen1, Wen Fu3, Xiaoqian Tian1, Susu Lou1, Jichen Ruan1, Jing He1,3, Haixia Zhou1. 1. Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. 2. Department of Clinical Laboratory, Biobank, Harbin Medical University Cancer Hospital, Harbin, China. 3. Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Abstract
BACKGROUND: Wilms tumor, derived from embryonic cells, accounts for a large proportion of pediatric renal tumors. MYCN encoded by MYCN proto-oncogene, a member of the MYC family, is a BHLH transcription factor. It plays a critical role in tumorigenesis and predicts poor clinical outcomes in various types of cancer. However, the role of MYCN remained unclarified in Wilms tumor. In this study, we investigated the association between MYCN gene polymorphisms and Wilms tumor susceptibility. METHODS: Four MYCN gene polymorphisms (rs57961569 G > A, rs9653226 T > C, rs13034994 A > G, and rs60226897 G > A) were genotyped in 183 cases and 603 controls. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between MYCN gene polymorphisms and Wilms tumor susceptibility. RESULTS: Overall, no significant association was found for any of the four MYCN gene polymorphisms. Interestingly, in the stratification analysis, the rs57961569 was found to be associated with decreased Wilms tumor susceptibility in the children older than 18 months (AOR = 0.65, 95% CI = 0.42-1.00, P = .050). Moreover, older children carrying 2-4 risk genotypes were at increased risk of Wilms tumor (OR = 1.55, 95% CI = 1.001-2.40, P = .0497). Haplotype GCAA was shown to significantly increased Wilms tumor risk (AOR = 2.40, 95% CI = 1.12-5.14, P = .024). CONCLUSION: Our study demonstrated that these MYCN gene polymorphisms might be low penetrant variants in Wilms tumor.
BACKGROUND:Wilms tumor, derived from embryonic cells, accounts for a large proportion of pediatric renal tumors. MYCN encoded by MYCN proto-oncogene, a member of the MYC family, is a BHLH transcription factor. It plays a critical role in tumorigenesis and predicts poor clinical outcomes in various types of cancer. However, the role of MYCN remained unclarified in Wilms tumor. In this study, we investigated the association between MYCN gene polymorphisms and Wilms tumor susceptibility. METHODS: Four MYCN gene polymorphisms (rs57961569 G > A, rs9653226 T > C, rs13034994 A > G, and rs60226897 G > A) were genotyped in 183 cases and 603 controls. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between MYCN gene polymorphisms and Wilms tumor susceptibility. RESULTS: Overall, no significant association was found for any of the four MYCN gene polymorphisms. Interestingly, in the stratification analysis, the rs57961569 was found to be associated with decreased Wilms tumor susceptibility in the children older than 18 months (AOR = 0.65, 95% CI = 0.42-1.00, P = .050). Moreover, older children carrying 2-4 risk genotypes were at increased risk of Wilms tumor (OR = 1.55, 95% CI = 1.001-2.40, P = .0497). Haplotype GCAA was shown to significantly increased Wilms tumor risk (AOR = 2.40, 95% CI = 1.12-5.14, P = .024). CONCLUSION: Our study demonstrated that these MYCN gene polymorphisms might be low penetrant variants in Wilms tumor.
Authors: Richard D Williams; Reem Al-Saadi; Tasnim Chagtai; Sergey Popov; Boo Messahel; Neil Sebire; Manfred Gessler; Jenny Wegert; Norbert Graf; Ivo Leuschner; Mike Hubank; Chris Jones; Gordan Vujanic; Kathy Pritchard-Jones Journal: Clin Cancer Res Date: 2010-03-23 Impact factor: 12.531
Authors: Eric J Gratias; Jeffrey S Dome; Lawrence J Jennings; Yueh-Yun Chi; Jing Tian; James Anderson; Paul Grundy; Elizabeth A Mullen; James I Geller; Conrad V Fernandez; Elizabeth J Perlman Journal: J Clin Oncol Date: 2016-07-11 Impact factor: 44.544
Authors: Johanna Dzieran; Aida Rodriguez Garcia; Ulrica Kristina Westermark; Aine Brigette Henley; Elena Eyre Sánchez; Catarina Träger; Henrik Johan Johansson; Janne Lehtiö; Marie Arsenian-Henriksson Journal: Proc Natl Acad Sci U S A Date: 2018-01-26 Impact factor: 11.205